MN HF3553

Requires the ombudsman for mental health and developmental disabilities to monitor treatment of individuals participating in University of Minnesota Department of Psychiatry clinical drug trials and ensure compliance with federal human subjects protections and Institutional Review Board requirements.

Authorizes the ombudsman to gather records related to clinical drug trials from the University of Minnesota Department of Psychiatry and requires the university to notify the ombudsman within 24 hours of any death or serious injury to a trial participant.

Prohibits retaliation or adverse action against individuals participating in drug trials or anyone who makes complaints, and protects complainant confidentiality upon request.

Requires the Board of Regents of the University of Minnesota to reimburse the ombudsman's office for costs incurred in monitoring drug trial participants.

Expands the Medical Review Subcommittee's authority to make preliminary determinations regarding deaths of clinical drug trial participants and to report findings to the Board of Regents of the University of Minnesota.